Connect with us

Technology

UBC AND THREAD EXPAND SITEPLUS OFFERING AND ACTIVE STUDIES WITH BIOPHARMA SPONSORS TO OPTIMIZE EVIDENCE GENERATION

Published

on

Collaboration augments full-featured central site model with additional research services and technology to widen recruitment access and improve the site and patient experience

KING OF PRUSSIA, Pa. and CARY, N.C., June 25, 2024 /PRNewswire/ — United BioSource LLC (UBC), a leading provider of evidence development solutions, and Thread®, a leading decentralized research, electronic clinical outcome assessment (eCOA) and consulting services provider, today announced the expansion of their SitePlus solution. This joint offering, the outcome of a successful six-year working relationship, has provided early recruitment and retention success for biopharma customers since its March 2023 launch. UBC and Thread have now expanded the solution to offer additional central site services and technology features for both post-approval research and Phase II/III interventional clinical trials.

SitePlus provides a next-generation research model that can be initiated from initial study design and launch or added alongside any ongoing Phase II-IV study nationwide. SitePlus offers a central site model which extends the reach of sites and widens the addressable patient population. The solution leverages a centralized technology platform to accelerate patient recruitment, facilitate home health engagement, securely capture data, and enable superior patient retention.

SitePlus combines UBC’s industry leading late-stage research solutions with Thread’s technology to empower central site study designs focused on patients while improving the research experience for all participating sites. It further enables biopharma sponsors to contract with UBC as a central research center inclusive of investigator and study coordinating center concierge support services. SitePlus connects UBC’s central principal investigator, home health, and patient coordinating center expertise with Thread’s unified technology platform and consulting services for data capture, virtual visits, and optimized patient engagement.

“Study designs that rely exclusively on brick-and-mortar site models can benefit from the enhancements SitePlus offers to help meet their patient enrollment and retention goals,” said Bekki Bracken Brown, President & Chief Executive Officer, UBC. “Studies leveraging a hybrid approach have seen success in reaching a more representative patient population, faster, and maintaining patient engagement. The Thread technology platform supports our central site offering by enabling a more flexible approach to patient recruitment and engagement and strengthens the return on evidence generation for our customers. “

UBC and Thread’s enterprise collaboration continues to enrich UBC’s modernized study designs and eCOA solutions that enable patient-centered research studies to be conducted in the clinic, in the home, and on-the-go.

“Based on strong early results with SitePlus for our joint customers, we are excited to expand its features to offer solutions in both interventional and post-approval research studies,” said Thread Co-Founder and CEO John Reites. “We appreciate UBC’s continued partnership and the feedback from our biopharma customers to add more value to this important innovative offering’s market growth.”

Learn more about SitePlus at www.AddSitePlus.com

About UBC
United BioSource LLC (UBC) is the leading provider of evidence development solutions with expertise in uniting evidence and access. UBC helps biopharma mitigate risk, address product hurdles, and demonstrate safety, efficacy, and value under real-world conditions. Underpinned by our scientific expertise, data and analytics, and innovative technologies, we offer our customers flexible solutions generating the relevant real-world data necessary to make more informed decisions earlier, meet stakeholder requirements, and, ultimately, drive better patient outcomes. For additional information, visit www.ubc.com.

About Thread
Thread’s® purpose is to leverage its decentralized research platform to enable studies for everyone, everywhere. The company’s uniquely combined clinical research technology and consulting services help life science organizations to design, operate, and scale next-generation research studies and electronic clinical outcome assessments (eCOA) programs for participants, sites, and study teams. Through its comprehensive platform and scientific expertise, Thread empowers studies to be accessible, efficient, and centered on the patient. Backed by health care investors Water Street Healthcare Partners and JLL Partners, Thread is recognized as a leader by Everest Group’s Decentralized Clinical Trial Product PEAK Matrix® Assessment 2021/2022 and positioned in the Leader’s Category of the 2022 IDC MarketScape for R&D Decentralized Clinical Trial Technology Solutions Vendor Assessment 2022. Visit Threadresearch.com to learn more. 

View original content to download multimedia:https://www.prnewswire.com/news-releases/ubc-and-thread-expand-siteplus-offering-and-active-studies-with-biopharma-sponsors-to-optimize-evidence-generation-302173322.html

SOURCE UBC; Thread

Continue Reading

Technology

Club Offers for Travel Enthusiasts in Canada

Published

on

By

TORONTO, Oct 23, 2026 /PRNewswire/ — Travelzoo® (NASDAQ: TZOO), the club for travel enthusiasts, announces three of many new Club Offers for Club Members in Canada.

Rigorously vetted and negotiated for us travel enthusiasts:

$799—COSTA RICA WEEK WITH FLIGHTS & CAR
We think fall is an ideal time to visit Costa Rica; the scenery is lush and the crowds are gone. Drive between volcanic Arenal and the idyllic beaches of Tamarindo on this seven-night trip. Since it’s not as busy, we were able to negotiate a price that saves members up to $648 on departures through mid-December.

$899—BARCELONA: 5 NIGHTS WITH FLIGHTS
Explore Barcelona’s world-class museums and architectural masterpieces in the quieter winter months to pack more into your trip. You won’t waste hours in lines and can access top restaurants that are fully booked in summer. We save $300 on travel this January and February, when temperatures are still spring-like. Roundtrip flights from Toronto, hotel and daily breakfast are included.

$999—ST. KITTS GETAWAY FOR 2, REG. $2083
Most visitors to St. Kitts book months in advance, but when we pointed out that travel enthusiasts are more spontaneous, this resort gave us a terrific rate for stays this November and December. Spend four nights in Frigate Bay and get an upgraded Oceanview room, too.

Are you a travel enthusiast? Join the club today: https://travelzoo.com

Who are we?
We, Travelzoo®, are the club for travel enthusiasts. We reach 30 million travellers. Club Members receive Club Offers negotiated and rigorously vetted by our deal experts around the globe. Our relationships with thousands of top travel companies give us access to irresistible deals. Our club and its benefits are built around the lifestyle of a modern travel enthusiast.

Media Contact: 
Amanda Ieraci – Toronto
+1 437 866 8540
aieraci@travelzoo.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/club-offers-for-travel-enthusiasts-in-canada-302918543.html

SOURCE Travelzoo

Continue Reading

Technology

Howard Hughes Holdings Set to Join S&P SmallCap 600

Published

on

By

NEW YORK, Oct. 23, 2026 /PRNewswire/ — Howard Hughes Holdings Inc. (NYSE: HHH) will replace Arcosa Inc. (NYSE: ACA) in the S&P SmallCap 600 effective prior to the opening of trading on Wednesday, October 28. S&P 500 constituent CRH plc (NYSE: CRH) has acquired Arcosa in a deal that closed today, October 23.

Following is a summary of the changes that will take place prior to the open of trading on the effective date:

Effective Date

Index Name  

Action

Company Name

Ticker

GICS Sector

October 28, 2026

S&P SmallCap 600

Addition

Howard Hughes Holdings

HHH

Real Estate

October 28, 2026

S&P SmallCap 600

Deletion

Arcosa

ACA

Industrials

ABOUT S&P DOW JONES INDICES

S&P Dow Jones Indices is the largest global resource for essential index-based concepts, data and research, and home to iconic financial market indicators, such as the S&P 500® and the Dow Jones Industrial Average®. More assets are invested in products based on our indices than products based on indices from any other provider in the world. Since Charles Dow invented the first index in 1884, S&P DJI has been innovating and developing indices across the spectrum of asset classes helping to define the way investors measure and trade the markets.

S&P Dow Jones Indices is a division of S&P Global (NYSE: SPGI), which provides essential intelligence for individuals, companies, and governments to make decisions with confidence. For more information, visit www.spglobal.com/spdji/en/. 

FOR MORE INFORMATION:

S&P Dow Jones Indices
index_services@spglobal.com

Media Inquiries
spdji.comms@spglobal.com

View original content:https://www.prnewswire.com/news-releases/howard-hughes-holdings-set-to-join-sp-smallcap-600-302918511.html

SOURCE S&P Dow Jones Indices

Continue Reading

Technology

Chelsea FC announces multi-year sleeve partnership with Sokin, the business payments and FX platform

Published

on

By

Chelsea FC name fast-growing fintech platform as Principal Partner

LONDON, Oct. 23, 2026 /PRNewswire/ — Chelsea Football Club has today announced a multi-year partnership with Sokin, the embedded finance and payments company used by businesses worldwide. Sokin will be named a Principal Partner and Official Business Payments and FX Partner of Chelsea FC and Chelsea FC Women.

As a Principal Partner, Sokin will be represented on the sleeves of the Chelsea FC men’s, women’s and academy home, away, and third kits from the 2026/27 season.

The partnership brings together two ambitious London-headquartered organisations with worldwide reach – a club with millions of fans across the world and a fintech platform through which businesses move more than $11 billion a year. A club of Chelsea’s scale works in many currencies every day, with partners, competitions and supporters around the world, and needs a financial partner built to handle that.

Sokin gives finance teams business payments, multi-currency accounts, foreign exchange, checkout and treasury in one place, so they spend less time juggling banks and providers and keep more of what they move.

As Official Business Payments and FX Partner, Sokin will simplify how Chelsea FC sends, receives and manages money in the currencies the club operates in.

The Sokin logo will feature on the sleeve of the Chelsea shirt for the first time [when the men’s team host Tottenham Hotspur at Stamford Bridge on Saturday 24th October.]

Jason Gannon, President at Chelsea FC said:

“At Chelsea, we seek to partner with organisations that share our ambition and innovative mindset. Sokin’s expertise in business payments, and their focus on making both simpler for the businesses they serve, makes them a natural fit for the Club. We are pleased to welcome Sokin to the Chelsea family and look forward to working together in the years ahead.”

Vroon Modgill, CEO and founder at Sokin said:

“Chelsea plays on the biggest stage in world football, and its business runs in dozens of currencies. Sokin was built for that with regulated, multi-currency payments and foreign exchange for organisations that operate internationally. We’re proud to be the platform behind the business payments and FX of one of the most iconic teams in football. Sokin’s platform serves businesses in more than 170 countries. We’re thrilled to be partners for the season ahead. An organisation as sophisticated as Chelsea doesn’t leave its finances to chance.”

About Sokin

Sokin is the financial layer global business runs on. Businesses can transact, convert and hold money in 70+ currencies across 170+ countries. Some businesses use Sokin to manage global finance in-house. Others build it into their products to power financial experiences for their customers. Businesses move more than $9 billion a year on licenses Sokin holds in 36+ countries and infrastructure Sokin owns. Founded in 2019, Sokin has raised over $100 million from investors including Morgan Stanley Expansion Capital and Prysm Capital.

About Chelsea Football Club

Chelsea Football Club is one of the biggest, most successful football clubs globally and our men’s team are reigning world champions, having won the four-yearly FIFA Club World Cup in 2025. Our women’s team, Chelsea Women, are also multiple trophy winners.

Founded in 1905, Chelsea is London’s most central football club, based at the iconic 40,000-capacity Stamford Bridge stadium. Nicknamed the Blues, the club lifted the Champions League for the first time in 2012 and domestically has won the Premier League five times, the FA Cup eight times, the Football League Cup five times and the Football League Championship once, in 1955.

The Chelsea Women’s team have enjoyed a huge amount of success and in 2025 won the FA Women’s Super League for a sixth consecutive year and the eighth time overall. The Women’s FA Cup has been won on six occasions. We have also captured the FA Women’s League Cup four times as well as reaching the UEFA Women’s Champions League final in 2021. In two seasons, 2020/21 and 2024/25, a domestic treble of trophies was secured.

The Chelsea Foundation boasts one of the most extensive community initiatives in sport, helping to improve the lives of children and young people all over the world.

Media Contacts:

Taina Biggs
taina.biggs@sokin.com 

Nerissa Chesterfield
nerissa.chesterfield@chelseafc.com 

View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/chelsea-fc-announces-multi-year-sleeve-partnership-with-sokin-the-business-payments-and-fx-platform-302918466.html

Continue Reading

Trending